Bevacizumab improves macular function in patients with myopic choroidal neovascularization

This prospective case series included 15 eyes with subfoveal choroidal neovascularization secondary to myopic choroidal neovascularization treated with one intravitreal injection of 1.25 mg bevacizumab. At 12 months patients showed significantly improved macular function as evidenced by increased BCVA and mean retinal sensitivity, improved fixation stability, and reduced central absolute scotoma area. A single injection was enough to halt CNV in most patients. Mean injection rate was 1.53.